Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4990MR)

This product GTTS-WQ4990MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4990MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4097MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ3016MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ12122MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ9653MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ13493MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ11887MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ2147MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW